A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein.
Sign Up to like & getrecommendations! Published in 2022 at "Vaccine"
DOI: 10.1016/j.vaccine.2022.02.070
Abstract: There is an urgent need for a safe and effective vaccine against dengue virus (DENV) which infects about 390 million humans per year. In the present study we combined modifications of two DENV proteins, the… read more here.
Keywords: envelope protein; denv; cediii ns1; vaccine candidate ... See more keywords